CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Enrollment progressing toward interim analysis, planned when 30-50% of subjects reach 6 months in study HOUSTON, Nov. 2, 2022 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the first patient in Europe has been enrolled and dosed in France in the Company’s ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

The release as fetched from its publisher. cnspharma.com ↗